KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Operating Leases: 2019-2025

Historic Operating Leases for Sarepta Therapeutics (SRPT) over the last 7 years, with Sep 2025 value amounting to $215.0 million.

  • Sarepta Therapeutics' Operating Leases rose 26.49% to $215.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 26.49%. This contributed to the annual value of $192.5 million for FY2024, which is 36.54% up from last year.
  • According to the latest figures from Q3 2025, Sarepta Therapeutics' Operating Leases is $215.0 million, which was up 0.29% from $214.4 million recorded in Q2 2025.
  • Over the past 5 years, Sarepta Therapeutics' Operating Leases peaked at $215.0 million during Q3 2025, and registered a low of $35.2 million during Q3 2022.
  • Moreover, its 3-year median value for Operating Leases was $143.6 million (2024), whereas its average is $158.2 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Operating Leases tumbled by 48.35% in 2021, and later soared by 282.50% in 2023.
  • Sarepta Therapeutics' Operating Leases (Quarterly) stood at $41.5 million in 2021, then surged by 38.70% to $57.6 million in 2022, then soared by 144.82% to $141.0 million in 2023, then spiked by 36.54% to $192.5 million in 2024, then climbed by 26.49% to $215.0 million in 2025.
  • Its last three reported values are $215.0 million in Q3 2025, $214.4 million for Q2 2025, and $205.5 million during Q1 2025.